BMPRIA is required for osteogenic differentiation and RANKL expression in adult bone marrow mesenchymal stromal cells.
Soma BiswasPing LiHongguang WuMd ShafiquzzamanShunichi MurakamiMichael D SchneiderYuji MishinaBaojie LiJing LiPublished in: Scientific reports (2018)
Bone morphogenetic proteins (BMPs) activate the canonical Smad1/5/8 and non-canonical Tak1-MAPK pathways via BMP receptors I and II to regulate skeletal development and bone remodeling. Specific ablation of Bmpr1a in immature osteoblasts, osteoblasts, or osteocytes results in an increase in cancellous bone mass, yet opposite results have been reported regarding the underlying mechanisms. Moreover, the role for BMPRIA-mediated signaling in bone marrow mesenchymal stromal cells (BM-MSCs) has not been explored. Here, we specifically ablated Bmpr1a in BM-MSCs in adult mice to study the function of BMPR1A in bone remodeling and found that the mutant mice showed an increase in cancellous and cortical bone mass, which was accompanied by a decrease in bone formation rate and a greater decrease in bone resorption. Decreased bone formation was associated with a defect in BM-MSC osteogenic differentiation whereas decreased bone resorption was associated with a decrease in RANKL production and osteoclastogenesis. However, ablation of Tak1, a critical non-canonical signaling molecule downstream of BMP receptors, in BM-MSCs at adult stage did not affect bone remodeling. These results suggest that BMP signaling through BMPRIA controls BM-MSC osteogenic differentiation/bone formation and RANKL expression/osteoclastogenesis in adult mice independent of Tak1 signaling.
Keyphrases
- bone loss
- mesenchymal stem cells
- bone marrow
- bone mineral density
- bone regeneration
- soft tissue
- umbilical cord
- poor prognosis
- postmenopausal women
- oxidative stress
- body composition
- type diabetes
- epithelial mesenchymal transition
- signaling pathway
- adipose tissue
- metabolic syndrome
- binding protein
- long non coding rna
- radiofrequency ablation